Figure 1From: Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease Kaplan-Meier survival estimate. Overall population, KRAS wild-type versus KRAS mutant. 1, Progression-free survival; 2, overall survival.Back to article page